| Recommendations | Consensus statement instruction | Ref. |
|---|---|---|
| Molecular genetic testing for definitive disease associated genes (currently KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2) should be offered to all patients with acquired LQTS who experienced drug‐induced TdP, are aged below 40 years and have a QTc >440 ms (males) and >450 ms (females) in the absence of culprit drug |
|
20 , 94 |
| Cascade family screening for the presence of pertinent variants should be considered when QT prolonging drugs are or could be prescribed |
|
Expert opinion |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.